Biogen Stock Surges After Alzheimer's Approval -- WSJ
By Charley Grant
U.S. health regulators have approved (https://www.wsj.com/articles/new-alzheimers-drug-approved-by-fda-promises-to-slow-disease-11673032312?mod=hpleadpos4) Biogen's new Alzheimer's disease drug, and stockholders are reaping the rewards.
Biogen shares were recently up 6% shortly after trading resumed on Friday; the stock had been halted shortly before word of the approval became public.
Shares of Eli Lilly, which has similar drugs under development, were up 1.5% on Friday.
NOTE: In-line links reference additional content of interest chosen by the WSJ news team.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
January 06, 2023 15:30 ET (20:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.